Organization | Amsterdam Molecular Therapeutics

Amsterdam Molecular Therapeutics Report issue

For profit Phase 3

Founded: Amsterdam Netherlands (1998)

Status: Acquired by UniQure N.V. (2012)

Organization Overview

First Clinical Trial

2007

NCT01109498

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2009

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (4)

alipogene tiparvovec (glybera) (2 trials)

cyclosporine (sandimmune) (2 trials)

methylprednisolone (medrol) (1 trial)

mycophenolate (CellCept) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hyperlipoproteinemia Type I (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 4